Insulin-derived amyloidosis without a palpable mass at the insulin injection site: A report of two cases.
J Diabetes Investig
; 11(4): 1002-1005, 2020 Jul.
Article
em En
| MEDLINE
| ID: mdl-31867887
ABSTRACT
To date, almost all case reports of insulin-derived amyloidosis described the presence of a subcutaneous mass that was observable on physical examination. This report presents two cases of insulin-derived amyloidosis without palpable masses at insulin injection sites. In both cases, blood glucose concentrations improved, and the insulin dose could be reduced by an average of 45% after changing the insulin injection sites. The insulin absorption at the site was reduced to at most 40% of that at a normal site in one case. Magnetic resonance imaging and ultrasonography were useful to screen and differentiate insulin-derived amyloidosis without a palpable mass. This report showed that insulin-derived amyloidosis without a palpable mass can be present at the insulin injection site, and has similar clinical effects to insulin-derived amyloidosis with palpable masses.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 2
/
Insulinas
/
Amiloidose
/
Hipoglicemiantes
/
Injeções Subcutâneas
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article